FDA OKs new Johnson & Johnson treatment for psoriasis
People with psoriasis will have a new treatment option, after U.S. regulators approved a drug from Johnson &Johnson
Psoriasis patients experience chronic systemic skin inflammation and develop cardiovascular comorbidities that shorten their lifespan. Whether cardiovascular disease is improved by treatment with current biologics that target disease-specific pathways is unclear. KC-Tie2 mice develop psoriasiform skin inflammation with increases in IL-23 and IL-17A and proinflammatory monocytosis and neutrophilia that precedes development of carotid artery thrombus formation. To examine whether targeted blockade of IL-23 or IL-17A in KC-Tie2 psoriasis mice improves cardiovascular outcomes, mice were treated systemically for 6 weeks with an...
AbstractGP2015 is the second biosimilar of the reference p75 TNF receptor-Fc fusion protein etanercept. It is approved for use in all indications for which reference etanercept is approved, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis and paediatric plaque psoriasis. GP2015 has similar physiochemical and pharmacodynamic properties to those of reference etanercept, and the pharmacokinetic biosimilarity of the agents has been shown in healthy volunteers. GP2015 demonstrated clinical efficacy equivalent to...
Targeting Ripk1 could be an effective treatment for skin conditions such as eczema and psoriasis, a study finds.
Linked Article: Gisondi. Br J Dermatol 2017; 177:837–844
Linked Article: Simpson et al. Br J Dermatol 2017; 177:742–750.
Linked Article: Nelson et al. Br J Dermatol 2017; 177:758–770.
Abhishek De, Tanumay Raychaudhury, Murlidhar Rajagopalan, Aarti Sarda, Nidhi SharmaIndian Journal of Dermatology 2017 62(5):533-535
Kenit P Ardeshna, Shylaja Someshwar, Shaurya Rohatgi, Hemangi R JerajaniIndian Journal of Dermatology 2017 62(5):537-538
Shekhar Neema, Anupam Das, Nalin Shankar SinghIndian Journal of Dermatology 2017 62(5):542-544